Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hill Street's (V)ia Regal sells out at Ontario store
2021-06-02 22:39 ET - News Release
Ms. Lori Senecal reports
(V)IA REGAL PINK GRAPE SPARKLER FAST OUT OF THE GATE WITH CONSUMERS AND RETAILERS
The initial shipment of Hill Street Beverage Company Inc.'s first cannabis infused beverage (V)ia Regal pink grape sparkler sold out within a matter of days after launching at the Ontario Cannabis Store (OCS) and select retailers. A new shipment is expected to be restocked and available in the coming days.
"We have received a steady stream of extremely positive messages from customers and retailers that were fortunate to be the first to experience our new (V)ia Regal Pink Grape Sparkler," said Reuban Nadesan, Head of Strategy & Corporate Development. "As (V)ia Regal Pink Grape Sparkler is Canada's first grape-based cannabis infused beverage, customers and budtenders have pointed to its unique grape-based bubbly flavour as a refreshing addition to the beverage shelf. Everyone at Hill Street is delighted that it is off to such a fast start."
(V)ia Regal Pink Grape Sparkler is an early entrant to the "craft beverage shelf" at the Ontario Cannabis Store. Hand-crafted, with clean, simple ingredients, the new bubbly beverage has already become in-demand at the OCS and among select retailers.
(V)ia Regal Pink Grape Sparkler is offered in a 355ml sleek can containing 10mg of THC and only 90 calories. Via Regal was developed and is manufactured exclusively through our partnership with Molecule Inc. The new beverage is available through the Ontario Cannabis Store and select retailers. Serve it chilled for delicious, refreshing summer enjoyment.
Extension of Expiring Warrants
The Company also announces that it has made an application to the TSX Venture Exchange to extend the expiry date of 4,241,654 warrants, which were issued in June 2019. Each warrant entitles the holder to purchase one common share in the capital of the Company at an exercise price of $0.40 per share. The Warrants are set to expire on June 7, 2021. The Company has applied to extend the expiry date until December 31, 2021. The proposed extension is subject to the approval of the TSX Venture Exchange.
About Hill Street Beverage Company Inc.
Hill Street Beverage Company is a progressive non-alcoholic beverage and cannabis solutions company. We are pioneering the space where craft consumer products meet bioscience by combining our deep CPG expertise and our rights to use Lexaria Bioscience Corp.'s ground-breaking DehydraTECH patent portfolio for product development, licensing and B2B sales of Cannabis ingredients.
Hill Street Beverages brands include Hill Street Craft Brewed Lager, and Vin(Zero), and have won numerous medals and accolades around the world. Hill Avenue Cannabis Brands include (V)ia Regal Pink and White Grape Sparklers.
We seek Safe Harbor.
© 2021 Canjex Publishing Ltd. All rights reserved.
It's encouraging to hear that it tastes better than some of the top brands in Canada, now if they could just produce enough to supply the Ontario market...
Hill Avenue Cannabis Co.
Here's one ladies review (not mine) of the Regal Pink Grape Sparkler. It's now sold out in Ontario.
"So, over the weekend, I tried (V)ia Regal Pink Grape Sparkler, and it is dangerously good! It is, in my opinion, the best drink available at OCS at the moment. It taste fantastic with no weird taste like Hexo drinks and Canopy drinks. I found there was NO cannabis taste and that's the way I like it. It's just a normal quality drink. Now, I split the drink in two because I cannot take more than 5mg in one shot. If I did drink the whole drink, I think I would be lying on the floor of my deck looking at stars all night long. My cannabis tolerance is not great. I could see some ladies drinking half a can and adding some sparking water to make it a full drinks. Cheers!"
Hill Street
A big thank you to all of the fans of (V)ia Regal™ Pink Grape Sparkler who helped us sell out less than 10 days after launching. We'll be back on the shelf soon so you can see what all the buzz is about!
New IR dude, 15:30
Hill Street, Still no Health Canada license, apparently they haven't even finished construction.
https://www.newsfilecorp.com/release/85517
It's says "The market is in highly oversold territory. Beware of a trend reversal." Not lexx.
Lexaria "The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.
Long term indicators fully support a continuation of the trend."
Here's a review (not mine) of Hill Street's new drink. I wouldn't use it simply because of all the sugar.
"I think regal is one of the top tasting cannabis drinks on the market so far. They did well, great taste and flavour profile. I don't like the fact there's 12g of sugar but it's still not the highest out there. (Tweed)
It will be a great summer drink and also a good alternative to alcohol."
Hill Street News
https://www.newsfilecorp.com/release/84890
Acquisition of Shares by HoldCo (St. Catharines) Ltd.
Toronto, Ontario--(Newsfile Corp. - May 21, 2021) - Hill Street Beverage Company Inc. (TSXV: BEER) ("Hill Street" or the "Company"): This press release is being disseminated by HoldCo (St. Catharines) Ltd. (the "Acquiror") as required by National Instrument 62-103 - The Early Warning System and Related Take-Over Bids and Insider Reporting Issues, in connection with its acquisition of securities of Hill Street.
Pursuant to a right of conversion under previously issued convertible debentures of the Company in the principal amount of $1,000,000 ("Convertible Debenture"), issued on May 1, 2020, as described in the press release of the Company dated May 4, 2020, the Acquiror acquired 20,000,000 common shares in the capital of the Company at a deemed purchase price of $0.05 per Common Share.
Prior to the acquisition, the Acquiror owned or controlled 21,797,855 Common Shares representing 11.80% of the 184,718,695 issued and outstanding Common Shares. After completion of the acquisition, the Acquiror owned or controlled 41,797,855 Common Shares, representing 20.42% of the 204,718,695 issued and outstanding Common Shares. The Acquiror is relying on the exemption set forth in Section 4.2 of National Instrument 62-104 - Take Over Bids and Issuer Bids, of the formal bid rules, on the basis that this transaction is being made pursuant to a private agreement between the Company and the Acquiror.
The Acquiror acquired the Common Shares for investment purposes. The Acquiror intends to review its investment in Company on a continuing basis and may, from time to time and at any time, acquire or cause to be acquired additional equity or debt securities or other instruments of Company, or dispose or cause to be disposed such equity or debt securities or instruments, through open market transactions, private placements by Company and other privately negotiated transactions, or otherwise, in each case in accordance with applicable securities laws.
An early warning report will be filed by the Acquiror under applicable securities laws and will be available on Company's SEDAR profile at www.sedar.com . A copy of the early warning report may also be obtained from James Leech, Corporate Secretary, jleech@torkinmanes.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Not for dissemination in the United States of America.
Soon. IMHO.
Unlimited upside if British American Tobacco has the same results with nicotine using the newest version of DehydraTECH 2.0 as Lexaria had with CBD absorption. Then there's the anti-virials, the hypertension, NSAIDs, viagra etc, etc.
HFTs playing their games, milking it for everything it's worth.
At the end of this presentation. 8 million fully diluted.
https://d1io3yog0oux5.cloudfront.net/_413e60bb0c0f444f0831793d0f5af6af/lexariabioscience/db/857/7404/pdf/2021-05+LEXX+Lexaria+Presentation+PDF+FINAL.pdf
8 million fully diluted, I believe.
The latest presentation as seen on Benzinga.
https://d1io3yog0oux5.cloudfront.net/_eb99cedefd1c974d3ddb83d5c41dde5b/lexariabioscience/db/857/7404/pdf/2021-05+LEXX+Lexaria+Presentation+PDF+FINAL.pdf
Finally a product using DehydraTECH for sale in Canada!
https://www.newsfilecorp.com/release/83820
ORIGINAL: Lexaria Strengthens its International Patent Portfolio to 19 Patents Granted
2021-05-12 07:05 ET - News Release
(via TheNewswire)
New patent granted in India bolsters worldwide patent coverage, adding to existing patents in the EU, the U.S., and Australia
Kelowna, British Columbia – TheNewswire - May 12, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces further expansion of its intellectual property portfolio with its first-ever patent granted in India.
The patent is titled “ Stable ready-to-drink beverage compositions comprising lipophilic active agents” and is of particular importance given the size of the Indian population, which is nearly four times as large as the U.S. population . The patent is valid for 20 years from the patent application date of Dec. 1, 2016.
“This is our 19 th patent granted worldwide, allowing us to innovate in the ready-to-drink beverage composition category around the world,” said Chris Bunka, CEO of Lexaria. “This new patent complements our existing suite of granted patents spanning the EU, the U.S., and Australia, and provides intellectual property protection to both consumer-packaged goods as well as registered drug applications. We believe these are robust growth categories that add to Lexaria’s strategic value.”
This is the second patent granted from Lexaria’s third patent family. Lexaria’s patent application suite has grown to a total of 13 patent families. Active ingredients that may be used under this new patent include NSAIDS (e.g., acetylsalicylic acid, ibuprofen, diclofenac, indomethacin, piroxicam), fat-soluble vitamins, and acetaminophen. Active ingredients under the new patent also include nicotine and cannabinoids.
Claims granted cover a wide range of product formats, including non-carbonated beverages, carbonated beverages, colas, root beers, fruit-flavoured beverages, citrus-flavored beverages, fruit juices, fruit-containing beverages, vegetable juices, vegetable-containing beverages, teas, coffees, dairy beverages, protein-containing beverages, shakes, sports drinks, energy drinks, and flavored waters.
Lexaria has patent applications progressing in countries around the world with aggregate populations of approximately 3.7 billion people and will report on further progress as information becomes available.
Perhaps we need to call our brokers and ask for our share certificates, I believe that this is the only way that you can avoid them being borrowed for shorting purposes. Thoughts!
BAT is working on a plant (tobacco) based vaccine. The delivery system is unknown.
https://www.cnn.com/videos/health/2021/05/04/new-vaccines-in-development-covid-future-pandemics-orig-mg.cnn/video/playlists/business-science-breakthroughs/
First time that I've seen a Sunday morning news release, is something brewing with Hill Street or maybe Lexy?
https://www.newsfilecorp.com/release/83404
I hear you, I've been holding so long I can't remember when I first bought in, I'll have to check my records to find out. I think it must be like 6 maybe 7 years now. I had 80,000 before the reverse split.
I still believe there's big things on the near horizon.
Nothing to worry about. Expect lots of volatility due to extremely small share float.
There's a big difference between short volume and short interest.
Whereas the term “short volume” measures the number of shares that have been shorted over a given period of time, “short interest” represents the number of shorted shares that have yet to be closed out or covered by investors. ...
Serious resistance around the $10 range, if we blow through here the sky is the limit.
In Bunka we trust!
Ask and thou shalt receive! LOL
Patience my friend, the word is spreading. We have to wade our way through day-traders and people dumping after holding forever. My faith is renewed once again. C'mon BAT.
You just know that if it does this with CBD that the results with nicotine and other pharmaceuticals will be similar!
NEWS
https://www.accesswire.com/644927/Lexaria-Issues-Successful-Results-from-First-2021-Study-HYPER-A21-1
Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1
(via TheNewswire)
• - Up to 2,178% more CBD delivered into bloodstream*
- Up to 1,737% more CBD delivered into brain tissue*
Kelowna, British Columbia – TheNewswire - May 6, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce successful outcomes in its first sets of data from its 2021 applied research and devel opment (R&D) study programs.
Study HYPER-A21-1 included three new “DehydraTECH 2.0” formulation variations designed to enable cannabidiol (“CBD”) delivery performance enhancements and pharmacokinetic optimization. All three new DehydraTECH 2.0 formulations delivered improved performance when compared to both Lexaria’s original DehydraTECH 1.0 and 2.0 concentration-matched formulations, as well as to a medium chain triglyceride (“MCT”) oil based control formulation representative of standard industry practices Summary data is shown below:
----------------------------------------------------------------------------------------------------------------------
|Formulation |AUClast (1) |% Improvement over MCT|% Improvement over |% Improvement over |
| | |Formulation |original DehydraTECH 1.0|original DehydraTECH 2.0|
| | (hr·kg·ng |(p value) |(p value) |(p value) |
| |/mL/mg) | | | |
|--------------------------------------------------------------------------------------------------------------------|
|MCT Control(2) |13.17± 6.78 |-- --- --- |
|--------------------------------------------------------------------------------------------------------------------|
|Original(2)DehydraTECH 1.0|64.6± 23.7 |390% | | |
| | |(p=0.00002) |-- --- |
|--------------------------------------------------------------------------------------------------------------------|
|Original(3)DehydraTECH 2.0|134.7± 63.7 |923% |108% |-- |
| | |(p=0.00009) |(p=0.0036) | |
|--------------------------------------------------------------------------------------------------------------------|
|**NEW**DehydraTECH | |1,068% |138% |14% |
|2.0 Formulation |153.9± 62.8 |(p=0.00003) |(p=0.0006) |(p=0.253) |
|1(4) | | | | |
|--------------------------------------------------------------------------------------------------------------------|
|**NEW**DehydraTECH | |1,540% |234% |60% |
|2.0 Formulation |216.0± 94.9 |(p=0.00004) |(p=0.0003) |(p=0.018) |
|2(4) | | | | |
|--------------------------------------------------------------------------------------------------------------------|
|**NEW**DehydraTECH | |2,178% |364% |123% |
|2.0 Formulation |300.1± 126.6 |(p=0.00007) |(p=0.0002) |(p=0.002) |
|3(4) | | | | |
----------------------------------------------------------------------------------------------------------------------
1. (1)AUC: Area Under the Curve, or total CBD delivery into the rodent bloodstream
2. (2)60-minute study duration
3. (3)60-minute study duration evaluated in 2019
4. (4)120-minute study duration evaluated in 2021
“Not only did the three latest DehydraTECH 2.0 formulations deliver between 1,068% and 2,178% more CBD during the study period than the standard MCT control formulation, they also were up to 123% more effective than the original DehydraTECH 2.0 formulation,” said Chris Bunka, CEO of Lexaria. “Said another way, for every 1 mg of CBD delivered by the industry standard MCT control formulation, these latest DehydraTECH 2.0 formulations delivered 10 to 21 mg of CBD.”
The study demonstrated that each of the new DehydraTECH 2.0 formulations delivered very high levels of CBD absorption into brain tissues, dwarfing the levels achieved with the MCT oil-based control formulation. The three new DehydraTECH 2.0 formulations delivered between 907%-1,737% more CBD into brain tissue than the MCT oil based control formulation, similar to the up to 1,937% increase over the MCT oil based control formulation announced previously for Lexaria's original DehydraTECH 2.0 formulation.
In each arm of the study, ten male Sprague-Dawley rats were dosed orally at a level of 25 mg/Kg CBD, and over the next 120 minutes multiple measurements were made of delivery into the bloodstream and tissues comparing the DehydraTECH formulations to certain controls.
These study findings add significantly to Lexaria’s body of evidence demonstrating the ability of its DehydraTECH technology to be engineered to enhance the delivery of lipophilic active ingredients such as CBD across a range of uptake levels, whereby higher delivery level targets may be most applicable to pharmaceutical dosage forms and lower delivery level targets more suited to consumer packaged goods.
Additional DehydraTECH 2.0 formulations are being evaluated in Lexaria study HYPER-A21-2 presently underway, and results are expected in late May or early June, 2021. Thereafter, Lexaria is planning additional work that will evaluate impacts upon real-time blood pressure in animals using select formulations pursuant to these studies. Lexaria will provide more details on this upcoming blood pressure testing in animals as they become available. As well, advanced DehydraTECH 2.0 formulations are already being used by Lexaria in ongoing human studies and will be monetized for commercial use when applicable.
* Compared with control formula utilizing medium chain triglycerides (coconut oil)representative of standard industry practices
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH has repeatedly demonstrated since 2016 with cannabinoids and nicotine the ability to increase bio-absorption by up to 5-10x, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is planned to be further evaluated for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), and nicotine. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 18 patents granted and approximately 60 patents pending worldwide. For more information, please visit www.lexariabioscience.com.
Wow! Isn't this sweet!
Hill Street Beverage 42,548,544-share private placement
Hill Street Beverage Company Inc (C:BEER)
Shares Issued 141,720,150
Last Close 4/29/2021 $0.085
Thursday April 29 2021 - Private Placement
The TSX Venture Exchange has accepted for filing documentation with respect to a non-brokered private placement announced on March 2, 2021, and further extended on March 4, 2021.
Number of shares:42,548,544 shares Purchase price:eight cents per share Warrants:42,548,544 share purchase warrants to purchase 42,548,544 shares Warrant exercise price:11 cents for a three-year period from the date of closing Number of placees:40 placeesInsiders:Raymond Bisaillon, 1,125,000; June Nicholson, 250,000; Lori Senecal, 250,000 Finder's fee:Echelon Wealth Partners, $8,320 in cash payment and 52,000 finder's warrants (Each finder's warrant will be exercisable for one common share of the company at an exercise price of eight cents for a two-year period of the date of issuance.)
© 2021 Canjex Publishing Ltd.
Hill Street, they're still threatening to enter the Canadian recreational cannabis market, some day! Still no license to produce anything, what a joke!
https://www.newsfilecorp.com/release/82220
Nothing a little shoe polish couldn't fix.
A pep talk to lift our spirits. LOL
We finally have enough revenue to cover Bunka's salary. LOL
The net loss has dropped by $1.7 million, not bad!